Connective Tissue Disease

Core Concepts

Connective tissue 101

Connective tissue is the body's supporting framework: collagen gives strength (tendons, ligaments, scars), elastin gives stretch (blood vessel walls, lungs, skin), and the surrounding ground substance holds cells and fluid. Connective tissue holds organs in place, transmits force at joints, and repairs damage. When the immune system turns against these structures, the damage shows up wherever the tissue is dense — joints, skin, blood vessels, kidneys, lungs, and eyes.

The autoimmune mechanism

Normally the immune system distinguishes "self" from "foreign." In CTDs, that tolerance breaks down: the immune system produces autoantibodies against self-proteins, and immune complexes (antibody–antigen clumps) deposit in tissues and trigger chronic inflammation. Over years, inflammation damages cartilage, bone, skin, blood vessels, and organs. Most CTDs are more common in women, often begin in young to middle adulthood, and typically follow a flare–remission pattern — quiet periods punctuated by flares that may be triggered by infection, sun exposure, stress, or sometimes nothing identifiable.

Rheumatoid arthritis — the prototype inflammatory arthritis

RA is a chronic autoimmune disease in which the synovium (joint lining) becomes inflamed and grows a destructive layer called pannus that erodes cartilage and bone. Hallmarks:

• Symmetric polyarthritis: both sides at once, typically the MCP joints, PIP joints, wrists, and knees — with the DIP joints (fingertip joints) characteristically spared, the mirror image of osteoarthritis.
• Inflammatory pain pattern: pain and stiffness at rest, prolonged morning stiffness (over an hour), improving with movement.
• Systemic features: fatigue, low-grade fever, weight loss, and rheumatoid nodules; the disease can also affect the lungs, heart, eyes, and blood vessels.
• Laboratory findings (conceptually): rheumatoid factor (RF) and anti-CCP antibodies are commonly tested; anti-CCP is more specific for RA. Inflammatory markers (ESR, CRP) are often elevated. No single test is diagnostic alone — diagnosis is a provider judgment combining history, exam, and labs.
• Management: early treatment with disease-modifying antirheumatic drugs (DMARDs) — methotrexate is the classic first-line example — and biologic agents for more severe disease, all prescribed by the rheumatology team. NSAIDs and short-term corticosteroids may help symptoms. The goal is remission and prevention of joint damage, which is why early referral matters.

Systemic lupus erythematosus (SLE)

SLE is the classic multisystem autoimmune disease. Signature features:

• Skin: the malar ("butterfly") rash across the cheeks and nose, photosensitivity (rashes triggered by sunlight), and other skin lesions.
• Joints: inflammatory joint pain and swelling, often symmetric.
• Kidneys: lupus nephritis — inflammation of the kidney that can be silent until advanced, so blood pressure and urine monitoring are nursing priorities.
• Blood and serosa: low blood counts (anemia, leukopenia, thrombocytopenia), and serositis — inflammation of the linings around the heart (pericarditis) or lungs (pleuritis).
• Labs: antinuclear antibody (ANA) is positive in most people with SLE, but ANA can be positive in many conditions — a positive ANA alone is not a lupus diagnosis.

SLE is far more common in women and in certain ethnic groups; flares can be triggered by sun exposure, infection, and stress. Management involves immunosuppressive therapy as prescribed, sun protection, infection precautions, and monitoring for organ involvement.

Systemic sclerosis (scleroderma)

Scleroderma means "hard skin": excess collagen causes fibrosis of skin and internal organs. Key features:

• Raynaud phenomenon: fingers turn white, then blue, then red with cold or stress — a common early sign of the broader disease.
• Skin tightening on the hands, face, and trunk; esophageal dysmotility causing reflux and swallowing difficulty.
• Serious organ involvement: pulmonary fibrosis and pulmonary hypertension, and a renal crisis with dangerous hypertension — making blood pressure monitoring essential.

Sjögren syndrome

Sjögren is an autoimmune attack on the exocrine (secreting) glands, causing sicca — dry eyes and dry mouth — and it frequently occurs alongside RA or SLE. Nursing touches include eye care, oral care, hydration, and monitoring for related complications.

Diagnosis and management themes across the CTDs

• Diagnosis is made by the provider from history, physical exam, autoantibody panels, inflammatory markers, imaging, and sometimes biopsy — no single test proves or excludes a CTD.
• Treatment goals: control inflammation, prevent organ and joint damage, manage symptoms, and minimize drug toxicity. The mainstays are NSAIDs and corticosteroids for symptom control (short-term where possible) and DMARDs/biologics for disease modification.
• Because these drugs are immunosuppressive: infection risk is elevated; patients should report fever promptly, practice good hand hygiene, avoid sick contacts, and receive vaccines according to their care team's guidance (some live vaccines are contraindicated while immunosuppressed — a provider decision).
• Multidisciplinary care: rheumatology, nephrology, cardiology, pulmonology, physical/occupational therapy, and nursing.

Nursing priorities

• Comprehensive assessment: joints (warmth, swelling, symmetry, stiffness timing), skin (rash, tightening, ulcers, color changes), mucous membranes (dry eyes/mouth, oral ulcers), cardiopulmonary (dyspnea, chest pain, blood pressure), and renal (edema, urine output, blood pressure).
• Pain, fatigue, and function: energy conservation, joint protection, pacing, and activity within tolerance.
• Medication teaching and monitoring: purpose and side effects of prescribed drugs, lab monitoring schedules as ordered, and infection precautions — including what to report and when.
• Sun protection for photosensitive patients (SLE): sunscreen, protective clothing, and minimizing midday sun.
• Patient education and support: the disease is chronic — teach flare recognition and self-management, coordinate referrals, and support emotional well-being.
• Scope note: diagnosis, autoantibody testing, and all medication decisions belong to the provider; the nurse assesses, teaches, monitors, and reports. Institutional protocols and scope of practice vary.

Common Confusions